Contents
-
news
-
Health
Near the completion of indigenous dengue vaccine of India; To hit the market by next year
A desi dengue vaccine is undergoing a third phase of clinical trials in India, a top Indian Medical Research Officer. Testing, to develop a vaccine to develop life-drank dengue fever, which kills thousands of people every year during the rainy season, includes more than 10,000 healthy adult participants from more than 15 states and center areas. According to news reports, the vaccine is expected to be a hit in the markets by the mid -year.

The test includes more than 10,000 healthy adult participants from more than 15 states and center areas.
India’s own dengue vaccine is currently in the final stages of trial, Balram Bhargava, former Director General of the Indian Council of Medical Research (ICMR), who has led the India’s fight against Kovid -19.
“India is developing its first indigenous tetraVantant dengue vaccine, dengiall, which is undergoing phase 3 clinical trials in collaboration with Ramban Biotech and ICMR. Phase 1 and 2 clinical trials of Indian vaccine formulation have achieved promising results,” Bhargawa told Times.
According to Bhargava, the test consists of more than 10,000 healthy adult participants from more than 15 states and center areas. Although Bhargava did not want to comment on when it could hit the market as it was no longer with ICMR, TOI has reported that the Middle-Next Year was very likely. According to news reports, the vaccine is expected to provide a shield against dengue outbreaks-May-September a common phenomenon in the country during the annual monsoon, which leads to a large number of incompatibility.
Dengue fever is a viral disease transmitted by infected mosquitoes, mainly Aedes ate mosquito. This causes a series of symptoms – from mild fever and serious complications such as dengue hemorrhagic fever and dengue shock syndrome.
While there is no specific treatment for dengue till now, treatment focuses on managing most of the symptoms and preventing complications.
In August last year, TetraVant Dengue Vaccine Strain (TV003/TV005) – Developed by the National Institute of Health, the US gave promising results in pregnancy and clinical trials worldwide. Pansia Biotech, one of the three Indian companies, is in the most advanced phase of development, to gain stress. The company has worked extensively on these strains to develop a full vaccine construction and keeps a process patent for this work. Phase 1 and 2 of Indian vaccine manufacturing completed in the clinical trials 2018-19, achieving promising results.
What is the reason for dengue?
Dengue fever is caused by one of the four dengue viruses. When a mosquito infected with the virus bites you, the virus enters your blood and makes itself copies – causing you to feel ill.
According to experts, the virus destroys parts of your blood that make clots and gives the structure to your blood vessels. This, with some chemicals that form your immune system, removes your blood from your vessels and causes internal bleeding. It leads to the symptoms of serious dengue life-threatening.
What are signs and symptoms of dengue fever?
Symptoms of dengue fever appear four to 10 days after mosquito bite and can last for three to seven days. 1 out of 20 people who get sick with dengue will develop severe dengue after their early symptoms fade. Most dengue infections do not lead any symptoms; However, if you are with them, with high fever, you may have
- rash
- Intense pain behind your eyes
- nausea and vomiting
- Muscle, bone and joint pain
Now get the latest news with health and braking news and top headlines worldwide.
IndiaRamsia BiotechBalaram BhargavaICMRNational Institutes of HealthAedesDengiyalDengue vaccineDengue vaccine test final phseSymptoms and symptoms of dengue fever